Circadian Rhythms Disruption

  • Guo-Dong Huang
  • Ya-Li Wang


Abnormal circadian rhythm is quite common in PD patients, such as sleep-wake cycles, motor symptoms fluctuation, endocrine changes, autonomic dysfunction, and so on. It may have a negative effect on life quality of the patients. In addition, the disrupted biorhythm may alter the anti-oxidative ability, the autophagy level, and the mitochondrial function and thus accelerate disease progression. Recent studies showed that biorhythm modification, such as light therapy and physical exercise, can improve the motor symptoms and delay disease progression. Based on this, neurological clinicians should get more attention to circadian dysfunction of PD, and the circadian therapy may be a new hopeful strategy for PD.


Circadian rhythms Parkinson’s disease 


  1. 1.
    Edgar RS, et al. Peroxiredoxins are conserved markers of circadian rhythms. Nature. 2012;485:459–64. Scholar
  2. 2.
    Konopka RJ, Benzer S. Clock mutants of Drosophila melanogaster. Proc Natl Acad Sci U S A. 1971;68:2112–6.CrossRefGoogle Scholar
  3. 3.
    Lowrey PL, Takahashi JS. Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu Rev Genomics Hum Genet. 2004;5:407–41. Scholar
  4. 4.
    Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci. 2003;4:649–61. Scholar
  5. 5.
    O’Neill JS, Reddy AB. Circadian clocks in human red blood cells. Nature. 2011;469:498–503. Scholar
  6. 6.
    Buhr ED, Takahashi JS. Molecular components of the mammalian circadian clock. Handb Exp Pharmacol. 2013;217:3–27. Scholar
  7. 7.
    Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol. 2010;72:517–49. Scholar
  8. 8.
    Liu AC, et al. Intercellular coupling confers robustness against mutations in the SCN circadian clock network. Cell. 2007;129:605–16. Scholar
  9. 9.
    Mohawk JA, Takahashi JS. Cell autonomy and synchrony of suprachiasmatic nucleus circadian oscillators. Trends Neurosci. 2011;34:349–58. Scholar
  10. 10.
    Buhr ED, Yoo SH, Takahashi JS. Temperature as a universal resetting cue for mammalian circadian oscillators. Science. 2010;330:379–85. Scholar
  11. 11.
    Yang X, Lamia KA, Evans RM. Nuclear receptors, metabolism, and the circadian clock. Cold Spring Harb Symp Quant Biol. 2007;72:387–94. Scholar
  12. 12.
    Huang N, et al. Crystal structure of the heterodimeric CLOCK:BMAL1 transcriptional activator complex. Science. 2012;337:189–94. Scholar
  13. 13.
    Kume K, et al. mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell. 1999;98:193–205.CrossRefGoogle Scholar
  14. 14.
    Busino L, et al. SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science. 2007;316:900–4. Scholar
  15. 15.
    Siepka SM, et al. Circadian mutant overtime reveals F-box protein FBXL3 regulation of cryptochrome and period gene expression. Cell. 2007;129:1011–23. Scholar
  16. 16.
    Sato TK, et al. A functional genomics strategy reveals Rora as a component of the mammalian circadian clock. Neuron. 2004;43:527–37. Scholar
  17. 17.
    Preitner N, et al. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell. 2002;110:251–60.CrossRefGoogle Scholar
  18. 18.
    Ukai-Tadenuma M, et al. Delay in feedback repression by cryptochrome 1 is required for circadian clock function. Cell. 2011;144:268–81. Scholar
  19. 19.
    Liu AC, et al. Redundant function of REV-ERBalpha and beta and non-essential role for Bmal1 cycling in transcriptional regulation of intracellular circadian rhythms. PLoS Genet. 2008;4:e1000023. Scholar
  20. 20.
    Crosio C, Cermakian N, Allis CD, Sassone-Corsi P. Light induces chromatin modification in cells of the mammalian circadian clock. Nat Neurosci. 2000;3:1241–7. Scholar
  21. 21.
    Doi M, Hirayama J, Sassone-Corsi P. Circadian regulator CLOCK is a histone acetyltransferase. Cell. 2006;125:497–508. Scholar
  22. 22.
    Duong HA, Robles MS, Knutti D, Weitz CJ. A molecular mechanism for circadian clock negative feedback. Science. 2011;332:1436–9. Scholar
  23. 23.
    Naruse Y, et al. Circadian and light-induced transcription of clock gene Per1 depends on histone acetylation and deacetylation. Mol Cell Biol. 2004;24:6278–87. Scholar
  24. 24.
    Feng D, et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science. 2011;331:1315–9. Scholar
  25. 25.
    Keene AC, Duboue ER. The origins and evolution of sleep. J Exp Biol. 2018;221:jeb159533. Scholar
  26. 26.
    Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999;354:1435–9. Scholar
  27. 27.
    Ding F, et al. Changes in the composition of brain interstitial ions control the sleep-wake cycle. Science. 2016;352:550–5. Scholar
  28. 28.
    Tononi G, Cirelli C. Sleep and the price of plasticity: from synaptic and cellular homeostasis to memory consolidation and integration. Neuron. 2014;81:12–34. Scholar
  29. 29.
    de Vivo L, et al. Ultrastructural evidence for synaptic scaling across the wake/sleep cycle. Science. 2017;355:507–10. Scholar
  30. 30.
    Marshall L, Helgadottir H, Molle M, Born J. Boosting slow oscillations during sleep potentiates memory. Nature. 2006;444:610–3. Scholar
  31. 31.
    Blum ID, Bell B, Wu MN. Time for bed: genetic mechanisms mediating the circadian regulation of sleep. Trends Genet. 2018;34:379–88. Scholar
  32. 32.
    Toh KL, et al. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science. 2001;291:1040–3.CrossRefGoogle Scholar
  33. 33.
    Patke A, et al. Mutation of the human circadian clock gene CRY1 in familial delayed sleep phase disorder. Cell. 2017;169:203–215 e213. Scholar
  34. 34.
    Zhang L, et al. A PERIOD3 variant causes a circadian phenotype and is associated with a seasonal mood trait. Proc Natl Acad Sci U S A. 2016;113:E1536–44. Scholar
  35. 35.
    Xu Y, et al. Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome. Nature. 2005;434:640–4. Scholar
  36. 36.
    Katzenberg D, et al. A CLOCK polymorphism associated with human diurnal preference. Sleep. 1998;21:569–76.CrossRefGoogle Scholar
  37. 37.
    Hirano A, et al. A Cryptochrome 2 mutation yields advanced sleep phase in humans. elife. 2016;5:e16695. Scholar
  38. 38.
    He Y, et al. The transcriptional repressor DEC2 regulates sleep length in mammals. Science. 2009;325:866–70. Scholar
  39. 39.
    Pellegrino R, et al. A novel BHLHE41 variant is associated with short sleep and resistance to sleep deprivation in humans. Sleep. 2014;37:1327–36. Scholar
  40. 40.
    Ebisawa T, et al. Association of structural polymorphisms in the human period3 gene with delayed sleep phase syndrome. EMBO Rep. 2001;2:342–6. Scholar
  41. 41.
    Wulff K, Gatti S, Wettstein JG, Foster RG. Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. Nat Rev Neurosci. 2010;11:589–99. Scholar
  42. 42.
    Sterniczuk R, Dyck RH, Laferla FM, Antle MC. Characterization of the 3xTg-AD mouse model of Alzheimer’s disease: part 1. Circadian changes. Brain Res. 2010;1348:139–48. Scholar
  43. 43.
    Kudo T, Loh DH, Truong D, Wu Y, Colwell CS. Circadian dysfunction in a mouse model of Parkinson’s disease. Exp Neurol. 2011;232:66–75. Scholar
  44. 44.
    Oakeshott S, et al. Circadian abnormalities in motor activity in a BAC transgenic mouse model of Huntington’s disease. PLoS Curr. 2011;3:RRN1225. Scholar
  45. 45.
    Kondratova AA, Kondratov RV. The circadian clock and pathology of the ageing brain. Nat Rev Neurosci. 2012;13:325–35. Scholar
  46. 46.
    Altun A, Ugur-Altun B. Melatonin: therapeutic and clinical utilization. Int J Clin Pract. 2007;61:835–45. Scholar
  47. 47.
    Reiter RJ, Acuna-Castroviejo D, Tan DX, Burkhardt S. Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann N Y Acad Sci. 2001;939:200–15.CrossRefGoogle Scholar
  48. 48.
    Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine. 2005;27:119–30.CrossRefGoogle Scholar
  49. 49.
    Bordet R, et al. Study of circadian melatonin secretion pattern at different stages of Parkinson’s disease. Clin Neuropharmacol. 2003;26:65–72.CrossRefGoogle Scholar
  50. 50.
    Bolitho SJ, et al. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. Sleep Med. 2014;15:342–7. Scholar
  51. 51.
    Videnovic A, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol. 2014;71:463–9. Scholar
  52. 52.
    Breen DP, et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 2014;71:589–95. Scholar
  53. 53.
    Feng Z, et al. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer’s disease. J Pineal Res. 2004;37:129–36. Scholar
  54. 54.
    Mishima K, et al. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer’s type with disturbed sleep-waking. Biol Psychiatry. 1999;45:417–21.CrossRefGoogle Scholar
  55. 55.
    Singer C, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep. 2003;26:893–901.CrossRefGoogle Scholar
  56. 56.
    Aziz NA, et al. Delayed onset of the diurnal melatonin rise in patients with Huntington’s disease. J Neurol. 2009;256:1961–5. Scholar
  57. 57.
    Kondratov RV, Vykhovanets O, Kondratova AA, Antoch MP. Antioxidant N-acetyl-L-cysteine ameliorates symptoms of premature aging associated with the deficiency of the circadian protein BMAL1. Aging (Albany NY). 2009;1:979–87. Scholar
  58. 58.
    Klionsky DJ. Autophagy revisited: a conversation with Christian de Duve. Autophagy. 2008;4:740–3.CrossRefGoogle Scholar
  59. 59.
    Ma D, Panda S, Lin JD. Temporal orchestration of circadian autophagy rhythm by C/EBPbeta. EMBO J. 2011;30:4642–51. Scholar
  60. 60.
    Reme C, Wirz-Justice A, Rhyner A, Hofmann S. Circadian rhythm in the light response of rat retinal disk-shedding and autophagy. Brain Res. 1986;369:356–60.CrossRefGoogle Scholar
  61. 61.
    Pfeifer U, Scheller H. A morphometric study of cellular autophagy including diurnal variations in kidney tubules of normal rats. J Cell Biol. 1975;64:608–21.CrossRefGoogle Scholar
  62. 62.
    Huang G, Zhang F, Ye Q, Wang H. The circadian clock regulates autophagy directly through the nuclear hormone receptor Nr1d1/rev-erbalpha and indirectly via Cebpb/(C/ebpbeta) in zebrafish. Autophagy. 2016;12:1292–309. Scholar
  63. 63.
    He Y, et al. Circadian rhythm of autophagy proteins in hippocampus is blunted by sleep fragmentation. Chronobiol Int. 2016;33:553–60. Scholar
  64. 64.
    Li S, Wang Y, Wang F, Hu LF, Liu CF. A new perspective for Parkinson’s disease: circadian rhythm. Neurosci Bull. 2017;33:62–72. Scholar
  65. 65.
    Rothman SM, Mattson MP. Sleep disturbances in Alzheimer’s and Parkinson’s diseases. NeuroMolecular Med. 2012;14:194–204. Scholar
  66. 66.
    Shen Y, Huang JY, Li J, Liu CF. Excessive daytime sleepiness in Parkinson’s disease: clinical implications and management. Chin Med J. 2018;131:974–81. Scholar
  67. 67.
    van Hilten JJ, et al. Diurnal effects of motor activity and fatigue in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1993;56:874–7.CrossRefGoogle Scholar
  68. 68.
    Bonuccelli U, et al. Diurnal motor variations to repeated doses of levodopa in Parkinson’s disease. Clin Neuropharmacol. 2000;23:28–33.CrossRefGoogle Scholar
  69. 69.
    Piccini P, et al. Diurnal worsening in Parkinson patients treated with levodopa. Riv Neurol. 1991;61:219–24.PubMedGoogle Scholar
  70. 70.
    Fertl E, Auff E, Doppelbauer A, Waldhauser F. Circadian secretion pattern of melatonin in Parkinson’s disease. J Neural Transm Park Dis Dement Sect. 1991;3:41–7.CrossRefGoogle Scholar
  71. 71.
    Breen DP, et al. Hypothalamic volume loss is associated with reduced melatonin output in Parkinson’s disease. Mov Disord. 2016;31:1062–6. Scholar
  72. 72.
    Bogaerts V, Theuns J, van Broeckhoven C. Genetic findings in Parkinson’s disease and translation into treatment: a leading role for mitochondria? Genes Brain Behav. 2008;7:129–51. Scholar
  73. 73.
    Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I. Twenty-four hour cortisol release profiles in patients with Alzheimer’s and Parkinson’s disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging. 1997;18:285–9.CrossRefGoogle Scholar
  74. 74.
    Mizobuchi M, Hineno T, Kakimoto Y, Hiratani K. Increase of plasma adrenocorticotrophin and cortisol in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated dogs. Brain Res. 1993;612:319–21.CrossRefGoogle Scholar
  75. 75.
    Zhong G, Bolitho S, Grunstein R, Naismith SL, Lewis SJ. The relationship between thermoregulation and REM sleep behaviour disorder in Parkinson’s disease. PLoS One. 2013;8:e72661. Scholar
  76. 76.
    Cagnacci A, et al. Effect of naloxone on body temperature in postmenopausal women with Parkinson’s disease. Life Sci. 1990;46:1241–7.CrossRefGoogle Scholar
  77. 77.
    Suzuki K, et al. Circadian variation of core body temperature in Parkinson disease patients with depression: a potential biological marker for depression in Parkinson disease. Neuropsychobiology. 2007;56:172–9. Scholar
  78. 78.
    Schmidt C, et al. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord. 2009;24:2136–42. Scholar
  79. 79.
    Ejaz AA, Sekhon IS, Munjal S. Characteristic findings on 24-h ambulatory blood pressure monitoring in a series of patients with Parkinson’s disease. Eur J Intern Med. 2006;17:417–20. Scholar
  80. 80.
    Berganzo K, et al. Nocturnal hypertension and dysautonomia in patients with Parkinson’s disease: are they related? J Neurol. 2013;260:1752–6. Scholar
  81. 81.
    Ruan GX, Allen GC, Yamazaki S, McMahon DG. An autonomous circadian clock in the inner mouse retina regulated by dopamine and GABA. PLoS Biol. 2008;6:e249. Scholar
  82. 82.
    Struck LK, Rodnitzky RL, Dobson JK. Circadian fluctuations of contrast sensitivity in Parkinson’s disease. Neurology. 1990;40:467–70.CrossRefGoogle Scholar
  83. 83.
    Cai Y, Liu S, Sothern RB, Xu S, Chan P. Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson’s disease. Eur J Neurol. 2010;17:550–4. Scholar
  84. 84.
    Ding H, et al. Decreased expression of Bmal2 in patients with Parkinson’s disease. Neurosci Lett. 2011;499:186–8. Scholar
  85. 85.
    Gu Z, et al. Association of ARNTL and PER1 genes with Parkinson’s disease: a case-control study of Han Chinese. Sci Rep. 2015;5:15891. Scholar
  86. 86.
    Hood S, et al. Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. J Neurosci. 2010;30:14046–58. Scholar
  87. 87.
    Mattam U, Jagota A. Daily rhythms of serotonin metabolism and the expression of clock genes in suprachiasmatic nucleus of rotenone-induced Parkinson’s disease male Wistar rat model and effect of melatonin administration. Biogerontology. 2015;16:109–23. Scholar
  88. 88.
    Lin Q, et al. Promoter methylation analysis of seven clock genes in Parkinson’s disease. Neurosci Lett. 2012;507:147–50. Scholar
  89. 89.
    Dudley CA, et al. Altered patterns of sleep and behavioral adaptability in NPAS2-deficient mice. Science. 2003;301:379–83. Scholar
  90. 90.
    Bunger MK, et al. Mop3 is an essential component of the master circadian pacemaker in mammals. Cell. 2000;103:1009–17.CrossRefGoogle Scholar
  91. 91.
    Xie Z, et al. Smooth-muscle BMAL1 participates in blood pressure circadian rhythm regulation. J Clin Invest. 2015;125:324–36. Scholar
  92. 92.
    Kandalepas PC, Mitchell JW, Gillette MU. Melatonin signal transduction pathways require E-box-mediated transcription of Per1 and Per2 to reset the SCN clock at dusk. PLoS One. 2016;11:e0157824. Scholar
  93. 93.
    Paus S, et al. Bright light therapy in Parkinson’s disease: a pilot study. Mov Disord. 2007;22:1495–8. Scholar
  94. 94.
    Willis GL, Turner EJ. Primary and secondary features of Parkinson’s disease improve with strategic exposure to bright light: a case series study. Chronobiol Int. 2007;24:521–37. Scholar
  95. 95.
    Willis GL, Moore C, Armstrong SM. A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease. Rev Neurosci. 2012;23:199–226. Scholar
  96. 96.
    Yamanaka Y, et al. Differential regulation of circadian melatonin rhythm and sleep-wake cycle by bright lights and nonphotic time cues in humans. Am J Physiol Regul Integr Comp Physiol. 2014;307:R546–57. Scholar
  97. 97.
    Yamanaka Y, et al. Morning and evening physical exercise differentially regulate the autonomic nervous system during nocturnal sleep in humans. Am J Physiol Regul Integr Comp Physiol. 2015;309:R1112–21. Scholar
  98. 98.
    Yasumoto Y, Nakao R, Oishi K. Free access to a running-wheel advances the phase of behavioral and physiological circadian rhythms and peripheral molecular clocks in mice. PLoS One. 2015;10:e0116476. Scholar
  99. 99.
    Fonken LK, et al. Microglia inflammatory responses are controlled by an intrinsic circadian clock. Brain Behav Immun. 2015;45:171–9. Scholar
  100. 100.
    Neufeld-Cohen A, et al. Circadian control of oscillations in mitochondrial rate-limiting enzymes and nutrient utilization by PERIOD proteins. Proc Natl Acad Sci U S A. 2016;113:E1673–82. Scholar
  101. 101.
    Li SY, et al. Long-term levodopa treatment accelerates the circadian rhythm dysfunction in a 6-hydroxydopamine rat model of Parkinson’s disease. Chin Med J. 2017;130:1085–92. Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Guo-Dong Huang
    • 1
  • Ya-Li Wang
    • 2
  1. 1.Department of NeurologyBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  2. 2.Department of NeurologySuzhou Municipal Hospital (North), Nanjing Medical UniversitySuzhouChina

Personalised recommendations